FDA approves Wegovy to reduce heart disease risk in adults with obesity or overweight

Wegovy (semaglutide) injection is now indicated to reduce the risk of CV death, MI, and stroke in adults with CV disease and either obesity or overweight—making it the first weight-loss medication to be approved for this purpose. Wegovy should be used in addition to a reduced-calorie diet and increased physical activity. Approval was based on results from the phase 3 SELECT trial (N>17,600), in which Wegovy recipients experienced a 20% reduced risk of CV death, MI, and stroke, compared with placebo.